<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542785</url>
  </required_header>
  <id_info>
    <org_study_id>REG-078-2019</org_study_id>
    <nct_id>NCT04542785</nct_id>
  </id_info>
  <brief_title>Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial</brief_title>
  <acronym>DanAF</acronym>
  <official_title>Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation (DanAF) Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holbaek Sygehus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Holbaek Sygehus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2%&#xD;
      in the western world. Atrial fibrillation is associated with an increased risk of death and&#xD;
      morbidity. The comparable effects of a lenient rate control strategy and a strict rate&#xD;
      control strategy in patients with atrial fibrillation are uncertain and only one trial has&#xD;
      assessed this previously in patients with permanent atrial fibrillation.&#xD;
&#xD;
      The investigators will therefore undertake a randomised, superiority trial at four hospitals&#xD;
      in Denmark.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 24, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Outcome assessors will be blinded. Participants will not be informed of the heart rate target or actual heart rate. Treatment providers managing the heart rate target will not be blinded as the intervention requires information of the heart rate. Other treatment providers will not be informed of the heart rate target.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Short Form-36 (SF-36) physical component score</measure>
    <time_frame>After 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive outside hospital</measure>
    <time_frame>After 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Effect on Quality of Life (AFEQT)</measure>
    <time_frame>After 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36) mental component score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality regardless of cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 year</time_frame>
    <description>Mortality regardless of cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>After 3 years</time_frame>
    <description>Mortality regardless of cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>Composite of all-cause mortality, stroke, myocardial infarction and cardiac arrest.</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Composite of all-cause mortality, stroke, myocardial infarction and cardiac arrest.</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Composite of all-cause mortality, stroke, myocardial infarction and cardiac arrest.</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>ICD-10 codes I60-I63.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>2 year</time_frame>
    <description>ICD-10 codes I60-I63.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>After 3 years</time_frame>
    <description>ICD-10 codes I60-I63.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalisation for worsening of heart failure</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalisation for worsening of heart failure</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalisation for worsening of heart failure</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital admissions</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital admissions</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital admissions</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six-minute walking distance</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six-minute walking distance</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six-minute walking distance</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity measured using a trial accelerometer or similar</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity measured using a trial accelerometer or similar</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity measured using a trial accelerometer or similar</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of sleep apnoea</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of sleep apnoea</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of sleep apnoea</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Various biomarkers</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Various biomarkers</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Various biomarkers</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Switch to rhythm control strategy</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Switch to rhythm control strategy</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Switch to rhythm control strategy</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Implantation of a pacemaker or cardioverter-defibrillator</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Implantation of a pacemaker or cardioverter-defibrillator</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Implantation of a pacemaker or cardioverter-defibrillator</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The questionnaire WorkQ</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The questionnaire WorkQ</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The questionnaire WorkQ</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Left ventricle dimensions</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Left ventricle dimensions</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Left ventricle dimensions</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - systolic and diastolic function</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - systolic and diastolic function</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - systolic and diastolic function</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Right ventricle dimension</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Right ventricle dimension</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Right ventricle dimension</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Atrial dimensions</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Atrial dimensions</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - Atrial dimensions</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - pulmonary pressure</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - pulmonary pressure</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiography - pulmonary pressure</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short Form-36 (SF-36) physical component score</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short Form-36 (SF-36) physical component score</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Days alive outside hospital</measure>
    <time_frame>After 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Days alive outside hospital</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Days alive outside hospital</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Atrial Fibrillation Effect on Quality of Life (AFEQT)</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Atrial Fibrillation Effect on Quality of Life (AFEQT)</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short Form-36 (SF-36) mental component score</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short Form-36 (SF-36) mental component score</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>After 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>After 3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <condition>Atrial Fibrillation Chronic</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Lenient rate control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strict rate control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treating physicians will target a resting heart rate a mean resting heart rate &lt; 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rate control</intervention_name>
    <description>Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.</description>
    <arm_group_label>Lenient rate control</arm_group_label>
    <arm_group_label>Strict rate control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants with atrial fibrillation (ECG confirmed and diagnosed by the treatment&#xD;
             provider) who at inclusion have either persistent (defined as atrial fibrillation for&#xD;
             more than 7days) or permanent atrial fibrillation (only rate control is considered&#xD;
             going forward).&#xD;
&#xD;
          2. Rate control must be accepted as being the primary management strategy going forward.&#xD;
             Consideration towards whether rhythm control is more appropriate must be considered,&#xD;
             especially given the results of the Early treatment of Atrial fibrillation for Stroke&#xD;
             prevention Trial (EAST).&#xD;
&#xD;
          3. Informed consent.&#xD;
&#xD;
          4. Adult (18 years or older).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No informed consent.&#xD;
&#xD;
          2. Initial heart rate under 80 bpm at rest (assessed via ECG before randomisation).&#xD;
&#xD;
          3. Less than 3 weeks of anticoagulation with new oral anticoagulants or 4 weeks with&#xD;
             efficient warfarin if indicated.&#xD;
&#xD;
          4. Participants dependent on a high ventricular rate to maintain a sufficient cardiac&#xD;
             output. This will be based on an individual assessment of the possible participant.&#xD;
&#xD;
             Such participants could be participants with heart failure, participants with a&#xD;
             haemodynamically significant valve dysfunction or severely dehydrated participants.&#xD;
&#xD;
             Other factors such as echocardiographic assessments, stability of the disease and&#xD;
             similar will be factored in when judging if a participant is dependent on a high&#xD;
             ventricular rate. Such a decision will be made before randomisation by the treatment&#xD;
             provider.&#xD;
&#xD;
          5. Participants who cannot tolerate a lenient rate control strategy (e.g. in case of&#xD;
             tachycardia induced cardiomyopathy). This will be based on an individual assessment of&#xD;
             the possible participant. Such a decision will be made before randomisation by the&#xD;
             treatment provider.&#xD;
&#xD;
          6. Participants who are haemodynamically unstable and therefore require immediate&#xD;
             electrical cardioversion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Feinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holbaek University Hospital/University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Feinberg, MD</last_name>
    <phone>+45 59484530</phone>
    <email>jorf@regionsjaelland.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holbæk Hospital</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua B Feinberg, MD</last_name>
      <phone>004550587215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital - Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Holbaek Sygehus</investigator_affiliation>
    <investigator_full_name>Joshua Rose-Hansen Feinberg</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Rate control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share anonymised data in a data repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Not possible to describe yet but will be made available within a timely manner after publication of results.</ipd_time_frame>
    <ipd_access_criteria>Sharing will abide by the General Data Protection Regulation and the Danish data protections laws.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

